Previous studies have showed that FoxA1 functioned as a transcriptional modulator to repress lipid accumulation in NAFLD via transcriptional regulation of target genes such as FABP1 and FATP2 [11, 12]. This evidence concerns the gene FABP1 and metabolic dysfunction-associated steatotic liver disease.